Vividion Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.vividion.com
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT06804824
- Locations
- 🇺🇸
START Mid West, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain, Ogden, Utah, United States
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorsAdvanced Hematologic Tumors
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06188208
- Locations
- 🇪🇸
Vall d'Hebron, Barcelona, Spain
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT05954312
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
© Copyright 2025. All Rights Reserved by MedPath